Table 3.
Risk of primary outcomes in clinically relevant subgroups of patients.
| Groups (n = number of patients after PSM) | All-cause death |
MACE |
Major Bleeding |
|||
|---|---|---|---|---|---|---|
| N events | HR (95% CI) | N events | HR (95% CI) | N events | HR (95% CI) | |
| Sex | ||||||
| Discontinued OAC males (n = 2813) | 425 (15.1) | 1.23 (1.07–1.41) | 401 (14.3) | 1.38 (1.19–1.60) | 276 (9.8) | 1.10 (0.93–1.30) |
| Maintained OAC males (n = 2813) | 367 (13.0) | 310 (11.0) | 264 (9.4) | |||
| Discontinued OAC females (n = 2877) | 364 (12.7) | 1.37 (1.17–1.60) | 393 (1.7) | 1.37 (1.18–1.59) | 237 (8.2) | 1.09 (0.91–1.31) |
| Maintained OAC females (n = 2877) | 285 (9.9) | 305 (10.6) | 229 (8.0) | |||
| Low BMI | ||||||
| Discontinued OAC with low BMI (n = 3104) | 422 (15.1) | 1.23 (0.99–1.54) | 145 (16.6) | 1.41 (1.01–1.80) | 106 (12.2) | 1.20 (0.91–1.58) |
| Continued OAC with low BMI (n = 3104) | 309 (11.1) | 111 (12.7) | 95 (10.9) | |||
| Discontinued OAC without low BMI (n = 3052) | 454 (13.1) | 1.17 (0.98–1.27) | 510 (14.8) | 1.44 (1.26–1.65) | 359 (10.4) | 1.10 (0.95–1.27) |
| Continued OAC without low BMI (n = 3052) | 427 (12.4) | 375 (10.9) | 341 (9.9) | |||
| CKD | ||||||
| Discontinued OAC with CKD (n = 1035) | 471 (15.2) | 1.22 (1.07–1.39) | 486 (15.7) | 1.43 (1.25–1.63) | 307 (9.9) | 1.07 (0.91–1.26) |
| Continued OAC with CKD (n = 1035) | 410 (13.2) | 364 (11.7) | 301 (9.7) | |||
| Discontinued OAC without CKD (n = 3052) | 388 (12.7) | 1.29 (1.11–1.50) | 392 (12.8) | 1.28 (1.11–1.49) | 255 (8.4) | 1.03 (0.87–1.22) |
| Continued OAC without CKD (n = 3052) | 320 (10.5) | 323 (10.6) | 261 (8.6) | |||
| Previous bleeding | ||||||
| Discontinued OAC with previous bleeding (n = 1585) | 231 (14.6) | 1.31 (1.08–1.59) | 246 (15.5) | 1.34 (1.11–1.62) | 234 (15.0) | 1.01 (0.84–1.20) |
| Continued OAC with previous bleeding (n = 1585) | 186 (11.7) | 194 (12.2) | 248 (15.6) | |||
| Discontinued OAC without previous bleeding (n = 4632) | 640 (13.8) | 1.26 (1.12–1.41) | 639 (13.8) | 1.45 (1.23–1.69) | 326 (7.0) | 1.15 (0.98–1.35) |
| Continued OAC without previous bleeding (n = 4632) | 542 (11.7) | 455 (9.8) | 299 (6.5) | |||
| Type of OAC | ||||||
| Discontinued OAC with previous warfarin (n = 1034) | 143 (13.8) | 1.08 (0.85–1.36) | 137 (13.2) | 1.49 (1.15–1.94) | 101 (9.8) | 1.20 (0.90–1.59) |
| Continued OAC with warfarin (n = 1034) | 138 (13.3) | 97 (9.4) | 88 (8.5) | |||
| Discontinued OAC with NOACs (n = 2477) | 327 (13.2) | 1.48 (1.25–1.75) | 352 (14.2) | 1.66 (1.40–1.96) | 192 (7.8) | 1.09 (0.89–1.33) |
| Continued OAC with NOACs (n = 2477) | 237 (9.6) | 227 (9.2) | 186 (7.5) | |||
BMI, Body Mass Index; CC, Clinical Complexity; CI, Confidence Interval; CKD, Chronic Kidney Disease; HR, Hazard Ratio; MACE, Major Cardiovascular Events; OAC, Oral Anticoagulant; PSM, Propensity Score Matching.